Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)
· seekingalpha.com
Mirum Pharma (MIRM) reports Phase 3 EXPAND LIVMARLI topline results Oct 12.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...